Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide By Ogkologos - August 28, 2025 164 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ISG/OS-2 and GEIS-33 studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma MOST POPULAR Dual Inhibition of LAG-3 and PD-1 in Patients with Previously Untreated... January 10, 2022 FDA Approves Bosutinib for Paediatric Patients with Chronic Myelogenous Leukaemia October 13, 2023 4 Ways to Manage Setbacks in Your Cancer Recovery: A Young... April 11, 2023 New on NCI’s Websites for September 2021 September 1, 2021 Load more HOT NEWS We have a Deal: What does the new UK-EU relationship mean... Darolutamide Maintenance Improves Outcomes in Patients with mCRPC Who Were Previously... Oncogenic Drivers Associated with Late Recurrence in Postmenopausal Women with ER-positive/HER2-negative... More Immunotherapy Options Approved for Treating Endometrial Cancer
